Adovir

Treatment of chronic hepatitis B in adults with evidence of active viral replication and elevated serum aminotransferases (ALT or AST) or histologically active disease.

Adefovir dipivoxil is converted intracellularly to adefovir diphosphate. It competitively inhibits HBV DNA polymerase (reverse transcriptase) and causes termination of the viral DNA chain. Oral bioavailability is ~59% and renal excretion is the primary elimination route.

Adults (normal renal function): 10 mg once daily. Renal Impairment: CrCl 20-49 mL/min: 10 mg every 48 hours; CrCl 10-19 mL/min: 10 mg every 72 hours; Hemodialysis: 10 mg every 7 days post-dialysis.

Common: Asthenia, headache, abdominal pain, nausea. Serious: Nephrotoxicity, severe acute exacerbation of hepatitis B upon discontinuation, lactic acidosis, and hepatomegaly with steatosis.

Pregnancy Category C. Use during pregnancy only if potential benefit justifies potential risk to fetus.

Pregnancy Category: C — always consult a doctor before taking during pregnancy.

Monitor renal function closely in at-risk patients and adjust dose. Perform periodic liver function monitoring post-discontinuation.

High doses (250-500 mg daily) cause gastrointestinal adverse effects. Provide supportive and symptomatic treatment.

Store at a cool, dry place protected from light and moisture. Keep out of reach of children.